Published in Invest Ophthalmol Vis Sci on March 01, 2017
The biology of VEGF and its receptors. Nat Med (2003) 32.13
VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol (2006) 5.00
Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci (1995) 4.83
Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development (1992) 4.69
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res (1999) 4.23
Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res (1990) 3.35
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res (2002) 3.19
Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci (2011) 3.19
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res (2004) 3.03
Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol (1998) 2.71
Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol (2010) 2.19
The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res (2009) 2.17
VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell (2012) 2.14
Pressures in the juxtacanalicular tissue and Schlemm's canal in monkeys. Exp Eye Res (1992) 1.88
Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res (1995) 1.77
Direct-recorded intraocular pressure variations in a human subject. Arch Ophthalmol (1969) 1.71
Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol (2006) 1.69
The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species. J Biol Chem (2009) 1.69
Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol (2010) 1.64
Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci (2008) 1.63
Schlemm's canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process. PLoS Biol (2014) 1.61
Effects of mechanical stretching on trabecular matrix metalloproteinases. Invest Ophthalmol Vis Sci (2001) 1.60
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology (1998) 1.58
Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol (2009) 1.48
High-molecular-weight aggregates in repackaged bevacizumab. Retina (2010) 1.45
Aqueous humor pathways through the trabecular meshwork and into Schlemm's canal in the cynomolgus monkey (Macaca irus). An electron microscopic study. Am J Ophthalmol (1972) 1.44
The mouse anterior chamber angle and trabecular meshwork develop without cell death. BMC Dev Biol (2001) 1.43
Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem (2002) 1.42
Modulation of outflow resistance by the pores of the inner wall endothelium. Invest Ophthalmol Vis Sci (1992) 1.40
The fine structure of the cribriform meshwork in normal and glaucomatous eyes as seen in tangential sections. Invest Ophthalmol Vis Sci (1981) 1.39
Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology (2011) 1.33
Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion. Invest Ophthalmol Vis Sci (2011) 1.27
Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice. Invest Ophthalmol Vis Sci (2014) 1.26
Multiplex cytokine analysis of aqueous humor in eyes with primary open-angle glaucoma, exfoliation glaucoma, and cataract. Invest Ophthalmol Vis Sci (2012) 1.24
The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. J Clin Invest (2014) 1.23
Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma (2002) 1.20
Current biology of VEGF-B and VEGF-C. Curr Opin Biotechnol (1999) 1.20
Oxidative stress in angiogenesis and vascular disease. Blood (2013) 1.19
ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation (2002) 1.18
Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci (2011) 1.17
Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes. Invest Ophthalmol Vis Sci (2012) 1.17
Two pore types in the inner-wall endothelium of Schlemm's canal. Invest Ophthalmol Vis Sci (1998) 1.17
Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2012) 1.15
Schlemm's canal endothelia, lymphatic, or blood vasculature? J Glaucoma (2007) 1.14
Gene expression profiling of TGFbeta2- and/or BMP7-treated trabecular meshwork cells: Identification of Smad7 as a critical inhibitor of TGF-beta2 signaling. Exp Eye Res (2009) 1.14
Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment. Retina (2009) 1.14
Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem (2005) 1.14
Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity. Circ Res (2010) 1.14
The pore density in the inner wall endothelium of Schlemm's canal of glaucomatous eyes. Invest Ophthalmol Vis Sci (2002) 1.13
24-hour IOP telemetry in the nonhuman primate: implant system performance and initial characterization of IOP at multiple timescales. Invest Ophthalmol Vis Sci (2011) 1.12
The relationship between pore density and outflow facility in human eyes. Invest Ophthalmol Vis Sci (1992) 1.12
Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina (2011) 1.11
Differential effects of vascular endothelial growth factor-C and placental growth factor-1 on the hydraulic conductivity of frog mesenteric capillaries. J Vasc Res (2001) 1.10
Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina (2013) 1.10
Clinical measurements of aqueous outflow. Am J Ophthalmol (1951) 1.09
Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther (2002) 1.09
Aspects of the development of Schlemm's canal. Exp Eye Res (1992) 1.08
Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J (2010) 1.07
Pulsatile motion of the trabecular meshwork in healthy human subjects quantified by phase-sensitive optical coherence tomography. Biomed Opt Express (2013) 1.05
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology (2009) 1.03
Protein markers and differentiation in culture for Schlemm's canal endothelial cells. Exp Eye Res (2011) 1.03
Altered mechanobiology of Schlemm's canal endothelial cells in glaucoma. Proc Natl Acad Sci U S A (2014) 1.03
Structural factors influencing outflow facility and its changeability under drugs. A study in Macaca arctoides. Invest Ophthalmol (1973) 1.03
The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int J Exp Pathol (1998) 1.01
Pilocarpine-induced dilation of Schlemm's canal and prevention of lumen collapse at elevated intraocular pressures in living mice visualized by OCT. Invest Ophthalmol Vis Sci (2014) 0.98
IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology (2010) 0.98
The role of the prostaglandin EP4 receptor in the regulation of human outflow facility. Invest Ophthalmol Vis Sci (2011) 0.98
Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol (2007) 0.97
Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol (2016) 0.95
In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma (2010) 0.94
The structure of the trabecular meshwork, its connections to the ciliary muscle, and the effect of pilocarpine on outflow facility in mice. Invest Ophthalmol Vis Sci (2014) 0.93
Colocalization of outflow segmentation and pores along the inner wall of Schlemm's canal. Exp Eye Res (2014) 0.93
Monitoring the VEGF level in aqueous humor of patients with ophthalmologically relevant diseases via ultrahigh sensitive paper-based ELISA. Biomaterials (2014) 0.92
Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro. Exp Cell Res (2003) 0.90
The role of VEGF 165b in pathophysiology. Cell Adh Migr (2012) 0.86
Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. Exp Eye Res (2013) 0.85
Cytoskeletal dependence of adenosine triphosphate release by human trabecular meshwork cells. Invest Ophthalmol Vis Sci (2011) 0.84
Measurement of Outflow Facility Using iPerfusion. PLoS One (2016) 0.84
Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. Isr Med Assoc J (2013) 0.84
Pigment epithelium-derived factor decreases outflow facility. Invest Ophthalmol Vis Sci (2013) 0.83
Schlemm's canal: more than meets the eye, lymphatics in disguise. J Clin Invest (2014) 0.83
Expression and role of VEGF--a in the ciliary body. Invest Ophthalmol Vis Sci (2012) 0.83
Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol (2014) 0.83
Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab. Int Ophthalmol (2011) 0.82
Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci (2017) 0.81
Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther (2013) 0.81
Flt1 and Flk1 mediate regulation of intraocular pressure and their double heterozygosity causes the buphthalmia in mice. Biochem Biophys Res Commun (2012) 0.81
The trabecular wall of Schlemm's canal: a study of the effects of pilocarpine by scanning electron microscopy. Br J Ophthalmol (1979) 0.80
Immunohistochemical characterization of dendritic cells and macrophages in the aqueous outflow pathways of the rat eye. Exp Eye Res (1992) 0.80
Distinctive distribution of HLA class II presenting and bone marrow derived cells in the anterior segment of human eyes. Curr Eye Res (1992) 0.78
Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model. Exp Eye Res (2016) 0.76
Vascular Endothelial Growth Factor-A Increases the Aqueous Humor Outflow Facility. PLoS One (2016) 0.76
Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma. Clin Experiment Ophthalmol (2015) 0.76
Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice. Invest Ophthalmol Vis Sci (2014) 1.26
Pilocarpine-induced dilation of Schlemm's canal and prevention of lumen collapse at elevated intraocular pressures in living mice visualized by OCT. Invest Ophthalmol Vis Sci (2014) 0.98
The structure of the trabecular meshwork, its connections to the ciliary muscle, and the effect of pilocarpine on outflow facility in mice. Invest Ophthalmol Vis Sci (2014) 0.93
Aqueous humor outflow: dynamics and disease. Invest Ophthalmol Vis Sci (2015) 0.89
Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci (2017) 0.81
Physical Factors Affecting Outflow Facility Measurements in Mice. Invest Ophthalmol Vis Sci (2015) 0.81
Shear stress-triggered nitric oxide release from Schlemm's canal cells. Invest Ophthalmol Vis Sci (2014) 0.79
Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms. Invest Ophthalmol Vis Sci (2016) 0.76
Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost. Invest Ophthalmol Vis Sci (2017) 0.75
Aqueous Humor Outflow Requires Active Cellular Metabolism in Mice. Invest Ophthalmol Vis Sci (2020) 0.75
Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents. Invest Ophthalmol Vis Sci (2017) 0.75